<DOC>
	<DOCNO>NCT00132041</DOCNO>
	<brief_summary>RATIONALE : Radiofrequency ablation use high-frequency , electric current kill tumor cell . CT- , MRI- , ultrasound-guided radiofrequency ablation may effective treatment liver cancer cirrhosis . PURPOSE : This phase II trial study well radiofrequency ablation work treat patient liver cancer cirrhosis .</brief_summary>
	<brief_title>Radiofrequency Ablation Treating Patients With Liver Cancer Cirrhosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 18-month successful disease control rate , define identifiable liver tumor CT scan , patient hepatocellular carcinoma cirrhosis treat solitary repetitive percutaneous radiofrequency ablation ( RFA ) . Secondary - Correlate tumor size , MELD score , number RFA treatment ( solitary repetitive ) 18-month successful disease control rate patient treated procedure . - Determine local remote intrahepatic extrahepatic tumor recurrence rate patient treated procedure . - Correlate local remote intrahepatic extrahepatic tumor recurrence rate 18-month successful disease control rate patient treated procedure . - Correlate tumor size local disease control rate patient treated procedure . - Correlate solitary repetitive RFA without local/regional tumor control development extrahepatic tumor patient . - Determine local tumor eradication rate , determine examination whole liver specimens CT scan , patient treat procedure . OUTLINE : This multicenter study . Patients stratify accord hepatic dysfunction use MELD score ( &lt; 15 vs 15-25 v &gt; 25 ) . Patients undergo placement ablation electrode percutaneously tumor ( ) CT scan , MRI , ultrasound guidance . Patients undergo percutaneous radiofrequency ablation ( RFA ) directly tumor ( ) 12 minute . Patients undergo CT scan liver within 1 week RFA treatment every 3 month 18 month . Patients residual recurrent intrahepatic tumor ( ) detectable 3-month subsequent CT scan undergo repeat RFA technically feasible clinically indicate 15 month initial RFA treatment . After completion study treatment , patient follow 1 day , 1 week , 1 month , every 3 month 18 month . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hepatocellular carcinoma ( HCC ) , meet 1 follow criterion : Histologically confirm HCC Discrete nonbiopsied hepatic tumor , meet 1 follow criterion : Hypervascular tumor &gt; 2 cm 2 imaging study Hypervascular tumor &gt; 2 cm single imaging study AND alphafetoprotein ≥ 400 ng/mL Discrete nonbiopsied hypervascular hepatic tumor 2 consecutive imaging study ( e.g. , CT scan MRI ) document tumor growth &gt; 1 cm diameter Histologically confirm cirrhosis OR typical finding cirrhosis ( i.e. , nodular liver , splenomegaly , varix , ascites ) CT scan and/or MRI scan Single hepatic tumor &gt; 3.0 cm ≤ 5.0 cm diameter OR 3 few hepatic tumor ≤ 3.0 cm diameter No excessive intrahepatic tumor burden ( i.e. , &gt; 3 hepatic tumor OR single hepatic tumor &gt; 5 cm OR 3 vague hypervascular nodule &gt; 1 cm ) Tumor ( ) ≥ 1 cm main , right , leave portal vein hollow viscera No hepatic portal vein tumor invasion Tumor ( ) &gt; 1 cm treatable percutaneous radiofrequency ablation No extrahepatic tumor Not surgical candidate due follow reason : Tumor unresectable location Comorbid disease Insufficient hepatic reserve PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic No uncorrectable coagulopathy Hepatic Not specify Renal Creatinine ≤ 2.0 mg/dL Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception No active symptomatic bacterial fungal infection newly diagnose and/or require treatment No absolute contraindication IV iodinate contrast ( i.e. , history significant contrast reaction mitigate appropriate premedication ) PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior concurrent chemotherapy HCC No prior concurrent chemoembolization HCC Endocrine therapy Not specify Radiotherapy No prior concurrent radiotherapy HCC Surgery No prior choledochoenteric anastomosis No prior sphincterotomy duodenal papilla Other No prior concurrent cryoablation HCC No prior concurrent therapy HCC At least 7 day since prior aspirin At least 24 hour since prior ibuprofen At least 12 hour since prior low molecular weight heparin preparation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
</DOC>